InvestorsHub Logo
Followers 28
Posts 2777
Boards Moderated 0
Alias Born 03/24/2019

Re: None

Tuesday, 05/30/2023 1:59:39 PM

Tuesday, May 30, 2023 1:59:39 PM

Post# of 36602
Revive's Bucillamine is still by far one the best opportunities across the dire OTCM at present. At this stage of their trials (and related FDA & industry exposure) plus the current low share price, the risk/reward is well worth me continuing taking personally.